Patient access to Enbrel® starts with a complex and highly controlled manufacturing process1,2
From 1998 to 2015, Enbrel® was subject to 20 manufacturing improvements,3 none of which had impact on efficacy/safety.3,4
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
Review a recent study that assessed the product quality of Enbrel® through 3 major manufacturing enhancements from 1998 to 2015
Review a recent study that assessed the immunogenicity, safety and efficacy of Enbrel® produced with its current, serum-free, high-capacity manufacturing process
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022